)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Respiratorius
Respiratorius (RESP) investor relations material
Respiratorius Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Q3 2026 revenue was 0 KSEK; loss after financial items was 1,761 KSEK, while business development focused on finding a partner for VAL001.
Management assessed existing funding as sufficient to continue operations through February 2027 under the adopted budget.
Financial highlights
Q3 revenue was 0 KSEK, unchanged YoY; Q3 result after financial items was -1,761 KSEK vs -1,447 KSEK YoY.
9M revenue was 0 KSEK; result after financial items was -5,269 KSEK vs -5,258 KSEK in 9M 2025.
Q3 EPS was -SEK 0.22 vs -SEK 0.18 YoY; 9M EPS was -SEK 0.67, unchanged YoY.
Outlook and guidance
Under the adopted budget, current funding is expected to support operations through February 2027.
The stated objective is to secure a partner agreement for VAL001; ongoing discussions include counterparties evaluating the candidate internally.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Respiratorius
- Improved financials and strong equity position support ongoing development and partnering for VAL001.RESP
Q2 2026 - Improved Q1 results, strong patent progress, and funding secured through February 2027.RESPQ1 2026
- VAL001 advanced with regulatory, scientific, and financial milestones; strong equity and market outlook.RESPQ4 2025
- Regulatory progress and new funding position VAL001 for next steps, with losses narrowing.RESPQ3 2025
- No revenue, continued losses, but major regulatory and commercial progress for VAL001.RESPQ2 2025
- US patent win for VAL001 and strong liquidity position mark a pivotal Q3 for Respiratorius.RESPQ3 2024
- Net loss narrowed and US patent for VAL001 granted, securing operations and future prospects.RESPQ2 2024
- VAL001 shows strong promise for DLBCL, but losses persist amid zero revenue.RESPQ1 2025
- Losses narrowed, funding secured, and US patent granted for lead cancer drug VAL001.RESPQ4 2024
Next Respiratorius earnings date
Q4 20269 Feb, 2027
Respiratorius
Next Respiratorius earnings date
Q4 20269 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Respiratorius AB is a Swedish biotechnology company focused on developing drug candidates for the treatment of various diseases, primarily cancer, COPD (Chronic Obstructive Pulmonary Disease), and asthma. Its lead project, VAL001, is aimed at enhancing the treatment of Diffuse Large B-Cell Lymphoma (DLBCL), the most common type of aggressive lymphoma. Additionally, the company is developing substances like the RESP series, which have bronchodilating effects for respiratory conditions such as COPD and asthma. Respiratorius is also working on a cardiovascular biomarker to aid in PET imaging diagnostics. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.